A new phase 3 clinical trial shows that combining two hormone therapies before and after surgery may improve outcomes for high-risk prostate cancer patients. Oncologists see this as a potential new standard of care.
CHICAGO – High-risk prostate cancer patients who opt for surgical treatment now have an additional option, according to the results of a phase 3 clinical trial called PROTEUS. The study found that combining two hormone therapies both before and after surgery was more effective than using just one hormone therapy in early-stage cases.
Traditionally, patients with high-risk prostate cancer face two primary treatment paths: surgical removal or a combination of radiation therapy and hormone therapy. However, the new findings suggest a third approach could be on the horizon—surgery combined with hormone therapy both pre- and post-operatively.
The PROTEUS trial demonstrated that this dual-hormone regimen significantly improved outcomes for high-risk prostate cancer patients compared to single hormone therapy before and after surgery. This breakthrough has garnered significant attention among oncologists, who are now considering it a potential new standard of care.
Emmanuel Antonarakis, a genitourinary medical oncologist at the University of Minnesota, heralded the results as a "watershed moment" in prostate cancer treatment in an editorial published in the New England Journal of Medicine. Many other experts share this view, believing that this new approach could revolutionize how high-risk prostate cancer is managed.
While some oncologists are optimistic about the potential benefits of this new regimen, others remain cautious. The results need to be validated through further research and clinical practice before they can be widely adopted as a standard treatment protocol. Nonetheless, the PROTEUS trial has opened up exciting possibilities for improving outcomes in high-risk prostate cancer patients.
As more data becomes available, oncologists will continue to evaluate this new hormone therapy approach. For now, it represents an important step forward in the ongoing battle against prostate cancer.
